Effectiveness of different variants of anticoagulant therapy in patients with pulmonary embolism are not high risk of death

Now for the treatment of pulmonary thromboembolism low risk of death, there are different options for anticoagulation. We compared their efficiency to determine the optimal treatment strategy. The high correlation of positive dynamics in the form of recanalization of leg veins and the pulmonary arteries, the timing of the start of treatment. However, these same patients, regardless of the version of anticoagulant therapy, marked by slow regression of signs of overload of the right heart. This suggests the possibility of developing chronic thromboembolic pulmonary hypertension, which requires dynamic monitoring and echocardiography after discharge from hospital. By its effective therapy with oral anticoagulants it is not inferior to the action of parenteral drugs with a subsequent transition to warfarin. In patients treated with parenteral anticoagulation with a subsequent transition to warfarin, as well as in the group of patients treated with rivaroxaban volume reduction of thrombotic masses in the pulmonary arteries, according to our research, it is faster than patients who used apixaban.